Journal
CRITICAL CARE MEDICINE
Volume 48, Issue 8, Pages E690-E697Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCM.0000000000004415
Keywords
biomarkers; high-mobility group box 1; insulin-like growth factor-binding protein 7; myoglobin; tissue inhibitor of metalloproteinases-2
Categories
Funding
- Else Kroner Fresenius Stiftung [2016_A97]
- German Research Foundation [KFO342/1, ZA428/18-1, ME5413/1-1, PA483/17-1]
Ask authors/readers for more resources
Objectives: We have previously shown that remote ischemic preconditioning reduces acute kidney injury (acute kidney injury) in high-risk patients undergoing cardiopulmonary bypass and that the protective effect is confined to patients who exhibit an increased urinary tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 in response to remote ischemic preconditioning. The purpose of this study was to determine the optimal intensity of remote ischemic preconditioning to induce required [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] changes and further explore mechanisms of remote ischemic preconditioning. Design: Observational and randomized controlled, double-blind clinical trial. Setting: University Hospital of Muenster, Germany. Patients: High-risk patients undergoing cardiac surgery as defined by the Cleveland Clinic Foundation Score. Interventions: In the interventional part, patients were randomized to receive either one of four different remote ischemic preconditioning doses (3 x 5 min, 3 x 7 min, 3 x 10 min remote ischemic preconditioning, or 3 x 5 min remote ischemic preconditioning + 2 x 10 min remote ischemic preconditioning in nonresponders) or sham-remote ischemic preconditioning (control). Measurements and Main Results: The primary endpoint of the interventional part was change in urinary [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] between pre- and postintervention. To examine secondary objectives including acute kidney injury incidence, we included an observational cohort. A total of 180 patients were included in the trial (n= 80 observational andn= 100 randomized controlled part [20 patients/group]). The mean age was 69.3 years (10.5 yr), 119 were men (66.1%). Absolute changes in [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] were significantly higher in all remote ischemic preconditioning groups when compared with controls (p< 0.01). Although we did not observe a dose-response relationship on absolute changes in [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] across the four different remote ischemic preconditioning groups, in the 15 patients failing to respond to the lowest dose, nine (60%) responded to a subsequent treatment at a higher intensity. Compared with controls, fewer patients receiving remote ischemic preconditioning developed acute kidney injury within 72 hours after surgery as defined by both Kidney Disease: Improving Global Outcomes criteria (30/80 [37.5%] vs 61/100 [61.0%];p= 0.003). Conclusions: All doses of remote ischemic preconditioning significantly increased [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] and significantly decreased acute kidney injury compared with controls. High-dose remote ischemic preconditioning could stimulate [tissue inhibitor of metalloproteinases-2]*[insulin-like growth factor-binding protein 7] increases in patients refractory to low-dose remote ischemic preconditioning.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available